Aclarion (NASDAQ:ACON) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Aclarion (NASDAQ:ACON) from a hold rating to a sell rating in a research note released on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Aclarion Trading Down 0.4%

Shares of NASDAQ:ACON opened at $2.58 on Friday. Aclarion has a 52 week low of $2.34 and a 52 week high of $229.50. The company’s 50 day moving average is $4.58 and its two-hundred day moving average is $6.39. The company has a market cap of $2.19 million, a PE ratio of -0.17 and a beta of 1.44.

Aclarion (NASDAQ:ACON) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.64) by ($0.29). The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. Aclarion had a negative return on equity of 67.53% and a negative net margin of 10,908.50%. As a group, equities research analysts expect that Aclarion will post -263.33 EPS for the current year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.